Home >> 4SC-202
Related Products
4SC-202 Class I HDAC inhibitor

Catalog No.B4106
Size Price Stock Qty
5mg
$100.00
In stock
10mg
$150.00
In stock
50mg
$450.00
In stock
100mg
$700.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

      

Sample solution is provided at 25 µL, 10mM.

Quality Control

Chemical structure

4SC-202

4SC-202 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

4SC-202 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 1186222-89-8 SDF N/A
Synonyms N/A
Chemical Name N/A
Canonical SMILES N/A
Formula C30H29N5O6S2 M.Wt 619.71
Solubility Soluble in DMSO Storage Store at -20°C
Shipping Condition Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Background

4SC-202 is a selective, potent and orally available inhibitor of histone deacetylases (HDAC) specific for class I HDAC isoenzymes with an IC50 value of about 1μM [1].

4SC-202 has been reported to selectively inhibit the recombinant class I HDAC isoenzymes with IC50 values of 1.2μM, 1.12μM and 0.57μM for HDAC-1, HDAC-2 and HDAC-3, respectively. In vitro studies, 4SC-202 has been revealed to induce hyperacetylation of histone H3 in a concentration-dependent fashion with an EC50 values of 1.1μM in HeLa and RKO cell lines. In addition, 4SC-202 has been demonstrated to induce a G2/M cell cycle arrest and enhance in sub G1 cells. In other words, 4SC-202 can induce the apoptotic in NSCLS cell lines. 4SC-202 has been noted to suppress proliferative activity in human cancer cell lines with a mean IC50 of 0.7μM.

In vivo studies, 4SC-202 has shown a good tolerability and dose-dependent effect on anti-tumour activity compared with other inhibitors in the A549NSCLC xenograft model and the RKO27 colon carcinoma model [1].

References:
[1] Henning S W, Doblhofer R, Kohlhof H, et al. 178 Preclinical characterization of 4SC-202, a novel isotype specific HDAC inhibitor[J]. European Journal of Cancer Supplements, 2010, 8(7): 61.